The new analysis was presented on June 24 at a joint meeting of the National Institutes of Health (NIH) Board of Scientific Advisors and National Cancer Advisory Board.

"This evidence demonstrates that not only is [low-dose CT] valuable in reducing mortality associated with lung cancer in high-risk patients, but it is also cost-effective," said Gail Rodriguez, executive director of MITA, in a statement. "MITA looks forward to ongoing collaboration with patient advocates and others in the imaging community to ensure access to this lifesaving technology."